Videos

Thierry Facon, MD, spoke about treatment combinations that have seen success in patients with multiple myeloma, as well as where future research should be focused.

Experts muse on the unmet needs of multiple myeloma, and exciting investigational therapies on the horizon.

A look at the role of bispecifics and CAR T-cell therapies in the multiple myeloma treatment landscape.

Drs Tom Powles and Brian Shimkus muse on the unmet needs of kidney cancers and treatments on the horizon to look forward to.

A discussion on how patient risk groups play into deciding on the appropriate treatment for renal cell carcinoma.

Drs Bishop and Bank close by outlining remaining unmet needs in CLL, emerging regimens, and hopes for the future of care.

Mehmet Asim Bilen, MD, summarizes recent advances in metastatic RCC and looks towards the future of the field.

Michael R. Bishop, MD, and Bruce B. Bank, MD, summarize key takeaways from the ELEVATE-RR study and discuss the clinical implications of using BTK inhibitors in patients with CLL.

Arnab Basu, MD, MPH, FACP, weighs in on novel therapeutic targets and emerging regimens that may further improve kidney cancer outcomes.

Drs Bishop and Bank discuss ELEVATE-RR safety data.

Drs. Cohen and Lewis close by outlining ongoing clinical trials in CRC and hopes for the future of care.

Dr Rafael Fonseca, MD, provides insight on the evidence around quadruplet versus triplet therapies in patients with newly diagnosed, transplant-eligible multiple myeloma, and how to select the appropriate treatment regimen for this patient population.

Sara Hurvitz, MD, spoke about ongoing clinical trials in which trastuzumab deruxtecan is being investigated with the use of brain metastases.

Jaffer A. Ajani, MD, spoke about the recent approvals of nivolumab plus ipilimumab and nivolumab plus chemotherapy for patients with esophageal squamous cell carcinoma.

Moving to the last patient case of newly diagnosed multiple myeloma, expert panelists work together to define patient frailty in this setting and discuss how frail patients are treated in practice.

Shared insight on optimizing selection and use of daratumumab-containing regimens in NDMM, with regard for clinical trial readouts in this setting.

Sara Hurvitz, MD, spoke which patients would benefit most from fam-trastuzumab deruxtecan and what the next research steps will be.

Sara Hurvitz, MD, spoke to the difficulty of treating HER2-positive and advanced HER2-positive breast cancer and how the efficacy of novel agents such as fam-trastuzumab deruxtecan-nxki could make a difference in treating the disease.

The Moffitt Marrowvingians take their turn questioning the Memorial Sloan Kettering Mavericks on their presented clinical trial data.

Xiaoli Mi, MD, presents data from a paper in Blood on the determination of outcomes for adolescents and young adults with ALL.

Varun Narendra, MD, describes a clinical trial that studied whether pediatric-inspired ALL regimens could be used in older adults with Philadelphia chromosome–positive ALL.

Before closing out their discussion on non–small cell lung cancer, experts share excitement for possible improvements in the setting of perioperative therapy.

Experts highlight emerging data and novel regimens that have the biggest potential to impact treatment and management of patients with urothelial cancer.

Experts comment on the utility of PARP inhibitors in UC and discuss data presented at ASCO GU 2022.

Experts consider when and if it would be appropriate to utilize targeted or immunotherapy in patients with EGFR exon 19 deletion–positive NSCLC.

Uday R. Popat, MD, spoke about where he sees future research efforts headed regarding post-transplant cyclophosphamide to prevent graft-vs-host disease for patients with acute myeloid leukemia after transplant and how these results could impact the standard of care.

Experts discuss the case of a woman with relapsed/refractory multiple myeloma and the available treatment options, including novel BCMA-targeted agents.

Brian Shimkus, MD, discusses how he chose between RCC combination therapies before CLEAR trial data, and how the data influences his decisions now.

Key opinion leaders describe the role of blood-based MRD testing in the transplant-ineligible multiple myeloma treatment landscape.

Dr Brian Shimkus describes how he doses lenvatinib for renal cell carcinoma treatment.